[Federal Register Volume 64, Number 193 (Wednesday, October 6, 1999)]
[Notices]
[Pages 54336-54338]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-25952]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
[[Page 54337]]
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National of
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential
Disclosure Agreement will be required to receive copies of the patent
applications.
Adenoviral Vector Expressing a SV4OT Antigen Antisense RNA
David S. Schrump, Z. Sheng Guo, Ishrat Wahseed (NCI)
Serial No. 60/124,776 filed 17 Mar 1999
Licensing Contact: Richard U. Rodriguez; 301/496-7056 ext. 287; e-mail:
rr154z@nih.gov
Desired nucleic acid sequences with therapeutic potential may be
introduced into mammalian cells using appropriate vectors. Antisense
technology is well known in the art and describes a mechanism whereby a
nucleic acid comprising a nucleotide sequences, which is in a
complementary, ``antisense'' orientation with respect to a coding or
``sense'' sequence of an endogenous gene, is introduced into a cell,
whereby a duplex forms between the antisense sequence and its
complementary sense sequence. The formation of this duplex results in
inactivation of the endogenous gene.
The present invention describes a method of treatment of cancer by
administering a replication-deficient recombinant adenovirus comprising
a nucleic acid that encodes an antisense rebonucleic acid to the SV40 T
antigene. In addition, it provides methods for reducing the level of
expression of SV40 T antigen, induction of apoptosis, effecting cell
growth arrest, reducing the levels of proto-oncogene expression,
unregulating pro-apoptotic proteins, maintaining normal levels of
functional p53, and maintaining normal levels of functional Rb, p107,
and p130. The types of cancers contemplated by this invention include
all cancers that express SV40 T antigen.
Aspartic Protease Inhibitors, Compositions, and Associated
Therapeutic methods
Ramnarayan S. Randad, John W. Erickson, Michael A. Eissenstat, Lucyna
Lubkowska (NCI)
Serial No. 60/114,868 filed 06 Jan 1999
Licensing Contact: John Peter Kim; 301/496-7056 ext. 264; e-mail:
jk141n@nih.gov
The human immunodeficiency virus (HIV) is the causative agent of
acquired immunodeficiency syndrome (AIDS). Drug-resistance is a
critical factor contributing to the gradual loss of clinical benefit to
treatments for HIV infection. Accordingly, combination therapies have
further evolved to address the mutating resistance of HIV. However,
there has been great concern regarding the apparent growing resistance
of HIV strains to current therapies.
The subject invention provides compounds which may serve as
therapeutic candidates for inhibition of HIV-1 PR (protease) and thus
serve in controlling AIDS, as well as having anti-malarial properties.
These compounds may be used in combination with other protease
inhibitors or inhibitors of HIV-1 reverse transcriptase, especially in
patients who have developed resistance to other HIV protease
inhibitors. These inhibitors have high potency, lower molecular weight,
and lower lipophilicity than previous compounds, as well as a better
profile towards drug resistant mutant strains of HIV.
2,5-Diamino-3,4-Disubstituted-1,6-Diphenylhexane Isosteres
Comprising Benzamide, Sulfonamide and Anthranilamide Subunits and
Methods of Using
Ramnarayan S. Randad and John W. Erickson (NCI)
Serial Nos. 09/039,669 and 09/039,670 filed 16 Mar 1998; Serial No. 08/
359,612 filed 20 Dec 1994
Licensing Contact: John Peter Kim; 301/496-7056, ext. 264; e-mail:
jk141n@nih.gov
The human immunodeficiency virus (HIV) is the causative agent of
acquired immunodeficiency syndrome (AIDS). Drug-resistance is a
critical factor contributing to the gradual loss of clinical benefit to
treatments for HIV infection. Accordingly, combination therapies have
further evolved to address the mutating resistance of HIV. However,
there has been great concern regarding the apparent growing resistance
of HIV strains to current therapies.
The subject invention provides for treatment and prevention of HIV
infection and/or AIDS. The invention provides for 2,5-diamino-3,4-
disubstituted-1,6-diphenylhexane (DAD) isosteres comprising benzamide,
sulfonamide, and anthranilamide subunits; a pharmaceutical composition
comprising such compounds; a method of using such compounds to treat
retroviral, specifically HIV and more specifically HIV-1 and HIV-2,
infections in mammals, particularly humans; a method of synthesizing
asymmetric DAD isosteres comprising benzamide, sulfonamide, and
anthranilamide subunits; and a method of using such compounds to assay
new compounds; for antiretroviral activity.
Novel Tumor Necrosis Factor Family Member, DRL, and Related
Compositions and Methods
MJ Lenardo, J Wang, Di Jiang (NIAID)
Serial No. 60/106,976 filed 04 Nov 1998
Licsening Contact: Susan S. Rucker; 301/496-7056 ext. 245; e-mail:
sr156v@nih.gov
The invention described and claimed in this patent application
relates the isolation, cloning and characterization of a ligand which
belongs to the TNF family of cytokines. This ligand, named DRL (also
known as APRIL and TNFSF13), is a type II membrane protein of 250 amino
acids. The gene encoding DRL is found on the short arm of chromosome 17
at 17 p11.2-12. Soluble DRL can be obtained by preparing a DRL-IgG
fusion protein utilizing the extracellular domain of DRL. DRL has been
demonstrated to play a significant role in T cell activation and is
able to induce crosslinking of the T cell receptor. It is also capable
of inducing T cell proliferation. These results suggest that DRL may be
a target to be exploited in the treatment of conditions related to
inappropriate T cell activation such as autoimmune diseases, tissue
rejection and graft vs. host disease.
Methods and Compositions of Chemokine-Tumor Antigen Fusion Proteins
as Cancer Vaccines
Larry W. Kwak, Arya Biragyn (NCI)
U.S. Provisional Patent Application 60/077,745 filed 12 Mar 1998
(corresponding to PCT/US99/05345 filed 12 Mar 1999)
Licensing Contact: Elaine Gese; 301/496-7056 ext. 282; e-mail:
3g46t@nih.gov
The current invention embodies a broad range of fusion proteins,
each of which consists of a chemokine and a tumor or viral antigen.
Administration of these fusion proteins, or a nucleic acid encoding the
fusion protein, elicits a specific and potent in vivo immune response
directed against the antigen, thereby effectively inhibiting the growth
of cells expressing that antigen. The fusion proteins or DNA vaccines
therefore represent potential vaccines for use against cancer and also
against human immunodeficiency virus (HIV) infection.
[[Page 54338]]
Dated: September 27, 1999.
Jack Spiegel,
Director, Division or Technology Development and Transfer, Office of
technology Transfer, National Institutes of Health.
[FR Doc. 99-25952 Filed 10-5-99; 8:45 am]
BILLING CODE 4140-01-M
